Remove 2006 Remove Drugs Remove Pharmaceuticals Remove Pharmacokinetics
article thumbnail

Sandoz receives approval by European Commission for Hyrimoz® (adalimumab) high-concentration formulation

The Pharma Data

As part of the comprehensive submission package to the European Marketing Authorization, Sandoz conducted a Phase I pharmacokinetics (PK) bridging study comparing its approved adalimumab 50 mg/mL 2 with the 100 mg/mL (HCF). About Sandoz Sandoz, a Novartis division, is a global leader in generic pharmaceuticals and biosimilars.

article thumbnail

Game-changing pan-TEAD inhibitor for solid tumours

Drug Target Review

TEAD proteins are crucial for tumour progression and drug resistance, making them an attractive focus for therapeutic interventions. Leveraging AI-guided structure-based drug design, Insilico’s research and development team generated an impressive portfolio of over 6,000 molecules and identified three highly promising hit series.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Antibody-drug conjugates payloads: then, now and next

Drug Target Review

Antibody-drug conjugates (ADCs) have been a groundbreaking approach to cancer treatment with their ability to deliver cytotoxic drugs directly to diseased cells while sparing healthy tissues. 1 However, efforts proved less effective than the original drugs, owing mostly to insufficient toxicity against cancer cells.

article thumbnail

TACACICLIB, AUR-102, AURIGENE

New Drug Approvals

2006 Mar 1; 20(5):601-12, 2006), in contrast with CDK9, which phosphorylates both Ser-2 and Ser-5 of the CTD heptad (Pinhero et al., For drug development, it is typically advantageous to employ individual stereoisomers as they exhibit marked differences in pharmacodynamic, pharmacokinetic, and toxicological properties.

article thumbnail

Metabolism of five membered nitrogen containing heterocycles

Metabolite Tales Blog

2 Figure 1 Not only does the carboxylic acid moiety of the infamous drug zomepirac undergo conjugation to an unstable acyl glucuronide, the pyrrole undergoes oxidative metabolism to an epoxide intermediate that can be trapped by glutathione (Figure 2). 2a Figure 2 Also reported are more complex “per-oxidative” oxidations.

article thumbnail

Analysis Life Sciences Thank You FDA finalizes new guidance on nonclinical assessment of potential immunotoxicity

Agency IQ

FDA finalizes new guidance on nonclinical assessment of potential immunotoxicity Late last week the FDA released a final guidance document containing recommendations on the nonclinical assessment of potential immunotoxicity for drugs and certain biologics.

FDA 40
article thumbnail

The evolution of assays for immuno-oncology research

Drug Discovery World

Evolution of such defence mechanisms can lead to multi-drug resistance, further disease progression, and cancer metastasis. Benefits over 2D monolayer culture include the possibility of investigating drug penetration and drug resistance offered by the tumour cells.

Research 130